platoseedplatoseed
Targeting the Tumor Ecosystem to address cancer drug resistance.
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Alixia is a biotech company focused on addressing cancer drug resistance by targeting the tumor ecosystem. Their approach emphasizes disrupting metabolic and inflammatory triggers across multiple cell types within the tumor microenvironment to enable more durable cancer treatments.
The company develops a research platform to study interactions in the tumor ecosystem, integrating biology, biophysics, computational chemistry and clinical input to identify molecules that impact a broad range of cells in the microenvironment. Their lead compounds are described as tumor ecosystem disruptors that affect metabolic and inflammatory triggers in cancer and quasi-cancerous cells, with a portfolio of preclinical programs across cancer, aging, neurodegeneration and immune/inflammatory indications.
Who it’s for: Biotech/pharmaceutical developers and researchers focused on oncology, cancer drug resistance and tumor microenvironment biology; potential collaborators in preclinical and translational cancer research.
Hiring; active research/portfolio in preclinical development; leadership with academic collaborators
Formerly “Guided Clarity” · why startups rename →
Combinations therapy by rational design
Using CRISPR to find treatments for cancer and inflammation
